Literature DB >> 12965081

Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes.

Gurveen Saberwal1, Eileen Broderick, Imke Janssen, Vilasini Shetty, Sairah Alvi, Laurie Lisak, Parameswaran Venugopal, Azra Raza, Suneel D Mundle.   

Abstract

An unusually high incidence of apoptosis in S-phase cells is characteristically found in the bone marrow (BM) of patients with myelodysplastic syndromes (MDS). Previously, E2F1, c-myc, and Cyclin D1 have been shown to bring about both S-phase changes and/or apoptotic changes. We have already found a stoichiometric imbalance between pRb and E2F1 causing deregulated E2F1 activity in these disorders. In the present study, we investigated the status of Cyclin D1 in relation to E2F1 and apoptosis in 19 patients with a confirmed diagnosis of MDS in comparison with 6 healthy donors. Cyclin D1 was localized immunohistochemically using a specific monoclonal antibody (1:150 dilution) in plastic-embedded BM sections. The nuclear localization of Cyclin D1 graded on a subjective rating scale of 0 (negligible staining) to 8+ (highest), demonstrated negligible levels in normal marrows (median 1+), and in 11/19 evaluable MDS marrows. In contrast, 8/19 MDS biopsies showed an almost four-fold increase in Cyclin D1 localization (p< or =0.001). A western blot analysis of E2F1 in corresponding bone marrow (BM) aspirate mononuclear cells (MNC) demonstrated that the MDS patients with elevated Cyclin D1 expression also had a significant increase in E2F1 protein (p< or =0.03). Additionally, these patients revealed higher levels of mRNA of one of the E2F1 transcriptional target genes, dihydrofolate reductase (DHFR, p=0.01). Subsequently, the relationship of Cyclin D1 with apoptosis was elucidated in a colocalization experiment in BM biopsy sections using immunohistochemistry for Cyclin D1 and in situ end labeling of DNA (ISEL) for apoptosis. The percentage of ISEL-positive apoptotic cells was several fold higher in MDS as compared to normal BMs (p=0.009). Interestingly, 7-41% (median 20%) of the apoptotic cells in different MDS BMs revealed co-localization of Cyclin D1 in their nucleus, whereas in normal BMs co-localization was virtually absent (p=0.008). Thus, it is possible that in a subset of MDS patients, apoptotic death of bone marrow cells may involve Cyclin D1/E2F1 pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965081     DOI: 10.1089/152581603322286079

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  6 in total

Review 1.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

2.  Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Authors:  Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Loretta Pfannes; Kelsey Loeliger; Zachary Tucker; Xin Tian; Minjung Kwak; Francois Wilhelm; Agnes S M Yong; Irina Maric; Manoj Maniar; Phillip Scheinberg; Jerome Groopman; Neal S Young; Elaine M Sloand
Journal:  Leuk Res       Date:  2012-04-21       Impact factor: 3.156

3.  Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes.

Authors:  Dominik Beck; Steve Ayers; Jianguo Wen; Miriam B Brandl; Tuan D Pham; Paul Webb; Chung-Che Chang; Xiaobo Zhou
Journal:  BMC Med Genomics       Date:  2011-02-23       Impact factor: 3.063

Review 4.  Stem Cells in the Myelodysplastic Syndromes.

Authors:  Di Zhan; Christopher Y Park
Journal:  Front Aging       Date:  2021-07-16

5.  GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.

Authors:  Laura Guerenne; Stéphanie Beurlet; Mohamed Said; Petra Gorombei; Carole Le Pogam; Fabien Guidez; Pierre de la Grange; Nader Omidvar; Valérie Vanneaux; Ken Mills; Ghulam J Mufti; Laure Sarda-Mantel; Maria Elena Noguera; Marika Pla; Pierre Fenaux; Rose Ann Padua; Christine Chomienne; Patricia Krief
Journal:  J Hematol Oncol       Date:  2016-01-27       Impact factor: 17.388

Review 6.  Techniques for detecting chromosomal aberrations in myelodysplastic syndromes.

Authors:  Qibin Song; Min Peng; Yuxin Chu; Shiang Huang
Journal:  Oncotarget       Date:  2017-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.